Magnetic Resonance-Guided Drug Delivery.
The use of clinical imaging modalities for the guidance of targeted drug delivery systems, known as image-guided drug delivery (IGDD), has emerged as a promising strategy for enhancing antitumor efficacy. MR imaging is particularly well suited for IGDD applications because of its ability to acquire images and quantitative measurements with high spatiotemporal resolution. The goal of IGDD strategies is to improve treatment outcomes by facilitating planning, real-time guidance, and personalization of pharmacologic interventions. This article reviews basic principles of targeted drug delivery and highlights the current status, emerging applications, and future paradigms of MR-guided drug delivery.
Center for Interventional Oncology, Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA.
Andrew S
AS
Mikhail
Center for Interventional Oncology, Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA; Philips Healthcare, 3000 Minuteman Road, Andover, MA 01810, USA.
Ari
A
Partanen
The Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center, 111 Michigan Avenue, Washington, DC 20010, USA.
Pavel
P
Yarmolenko
Section of Abdominal Imaging, Department of Diagnostic Radiology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009, USA.
Aradhana M
AM
Venkatesan
Center for Interventional Oncology, Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA. Electronic address: bwood@nih.gov.
Bradford J
BJ
Wood
D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D053783:Magnetic Resonance Imaging, Interventional / Q000379:methods*
Cancer; Drug delivery; High-intensity focused ultrasound; Imaging guidance; MR imaging; Nanomedicine; Thermosensitive liposome; Tumor targeting